Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Pulse

Access to effective TB treatment a human right, countries declare

Barbara Sibbald
CMAJ May 16, 2000 162 (10) 1470-1471;
Barbara Sibbald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Multidrug-resistant strains of tuberculosis have already cost cities like New York and countries like Russia hundreds of lives and more than $1 billion each, and these strains will continue to emerge unless countries act quickly to strengthen their control over the disease, the World Health Organization says.

A new report from WHO and the International Union against TB and Lung Disease indicates that resistance to at least 1 TB drug has increased by 50% in both Denmark and Germany since 1996, and doubled in New Zealand. In all 3 countries, foreign-born TB patients are nearly twice as likely as native-born patients to be harbouring a drug-resistant strain.

"Improved screening of immigrants will not solve this problem," said Dr. Arata Kochi, director of the Stop TB Initiative. "The only safeguard for wealthy countries is to help countries with poorly functioning TB-control programs to fix the problem immediately by helping them strengthen their programs."

To this end, 20 countries attending the Ministerial Conference on TB and Sustainable Development, held in Amsterdam Mar. 24, declared that global access to effective TB treatment is a human right and a government's responsibility. This means that countries must provide anti-TB drugs, unhindered access to TB treatment, effective means of delivering treatment and affordable medicine for people who develop drug-resistant TB. They also identified the need for stronger, faster-acting drugs and an effective vaccine.

As an initial step, all 20 countries agreed to use the WHO's DOTS system (directly observed treatment - short course) with the aim of detecting 70% of all infectious cases by 2005. DOTS combines 5 elements - political commitment, microscopy services, drug supplies, surveillance and monitoring systems, and use of highly efficacious regimes - with direct observation of the patient while the drug is being taken; direct observation means that problems with patient compliance are all but eliminated. It produces cure rates of up to 95% in even the poorest countries and is ranked as one of the "most cost-effective of all health interventions" by the World Bank. A 6-month supply of drugs for DOTS treatment costs as low as US$11 per patient in some parts of the world.

"I am optimistic about the prospects for success," said Dr. Donna Shalala, secretary of health and human services in the US. Between 1982 and 1992, the number of TB cases in New York City tripled. Nearly 4000 people developed the disease in 1992, and one-third of them would not respond to one or more of the usual medicines. More than 500 of these patients eventually died. Shalala emphasized the need to "fight epidemics globally to protect people locally."

PreviousNext
Back to top

In this issue

CMAJ
Vol. 162, Issue 10
16 May 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Access to effective TB treatment a human right, countries declare
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Access to effective TB treatment a human right, countries declare
Barbara Sibbald
CMAJ May 2000, 162 (10) 1470-1471;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Access to effective TB treatment a human right, countries declare
Barbara Sibbald
CMAJ May 2000, 162 (10) 1470-1471;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • RSI placing a strain on workplace
  • Diabetes' rising toll
  • More than half of MDs under age 35 now using PDAs
Show more Pulse

Similar Articles

Collections

  • Topics
    • Global health
    • Human rights
    • Infectious diseases

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire